IPSC
Century Therapeutics, Inc.
There isn't enough reported data to score IPSC yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IPSC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
IPSC's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IPSC PE Valuation
IPSC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IPSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect IPSC's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IPSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.34 |
| Q2 2026 | -$0.93 | -$0.66 |
| Q1 2026 | -$1.14 | -$0.87 |
| Q4 2025 | -$0.14 | +$1.47 |
| Q3 2025 | -$0.30 | +$1.53 |
| Q2 2025 | -$0.27 | +$1.74 |
| Q1 2025 | -$0.27 | +$1.92 |
| Q4 2024 | -$1.61 | +$0.66 |
IPSC is still losing money, but far less than before: $0.64 per share over the past year, against $3.11 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IPSC on earnings quality, reporting a profit while its opponent remains loss making.
IPSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $109.2M | +12668% |
| Q4 2024 | $4.2M | +1457% |
| Q3 2024 | $791K | +434% |
| Q2 2024 | $771K | +679% |
| Q1 2024 | $855K | -50% |
| Q4 2023 | $268K | -49% |
| Q3 2023 | $148K | -93% |
| Q2 2023 | $99K | -93% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for IPSC versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | 68% | +3730 points |
| Q4 2024 | -893% | +15436 points |
| Q3 2024 | -4398% | +19674 points |
| Q2 2024 | -4508% | +30924 points |
| Q1 2024 | -3662% | -1797 points |
| Q4 2023 | -16329% | -9936 points |
| Q3 2023 | -24072% | -22645 points |
| Q2 2023 | -35431% | -33186 points |
IPSC's operating margin was 68% last quarter, up 3730 points from the same quarter a year ago, near the top of its range since 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IPSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.8M | +$3M |
| Q2 2026 | -$20.5M | +$7.4M |
| Q1 2026 | -$25.8M | +$9.3M |
| Q2 2025 | -$27.9M | -$312K |
| Q1 2025 | -$35.1M | -$4.3M |
| Q2 2024 | -$27.6M | -$3.8M |
| Q1 2024 | -$30.8M | +$3.4M |
| Q4 2023 | -$27.2M | +$2M |
IPSC has burned cash in almost every quarter: −$85M over the past year, against −$116M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IPSC on cash generation, producing positive trailing cash flow while its opponent burns cash.
IPSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +661K shares |
| 1 year | +139% | +120M shares |
| 3 years | +248% | +147M shares |
| 5 years | +277% | +152M shares |
| Available history | +394% | +165M shares |
IPSC has 206M diluted shares, up 139% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IPSC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IPSC Net Leverage
IPSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IPSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 36.3 | Neutral |
IPSC's weekly RSI is 44 (neutral) and its Stochastic is 36 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IPSC PE vs Healthcare Sector
IPSC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IPSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.54 | 5.8% above |
| 20 week MA | $1.86 | 12% below |
| 50 week MA | $1.94 | 16% below |
| 100 week MA | $1.28 | 27% above |
| 200 week MA | $2.06 | 21% below |
IPSC's trend is mixed: it's above two of its five weekly moving averages, and 21% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IPSC on trend strength, trading above more of its moving averages.
IPSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $22.8 | $18.2 | -20% |
| 2022 | $18.2 | $5.67 | -69% |
| 2023 | $5.67 | $3.32 | -41% |
| 2024 | $3.32 | $1.04 | -69% |
| 2025 | $1.04 | $1.09 | +4.8% |
| 2026 YTD | $1.09 | $1.63 | +50% |
IPSC has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.